Pei-Hsinq Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pei-Hsinq Lai has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Hsun Lu
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications - Song-Chou Hsieh
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications - Chiao-Feng Cheng
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2 shared publications - Ting-Yuan Lan
Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
2 shared publications Cheng-Han Wu
Division of Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu branch , Hsin-Chu
1 shared publication- Chieh-Yu Shen
Division of Rheumatology, Immunology & Allergy, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100115, Taiwan
1 shared publication
Latest Publications
- 6 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6168-6175
Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap
Objective: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents—Janus kinase inhibitors (JAKis)—remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. Method: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc–positive patients. Results: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc–positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. Conclusion: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.
- 6 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6168-6175
Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap
Objective: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents—Janus kinase inhibitors (JAKis)—remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. Method: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc–positive patients. Results: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc–positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. Conclusion: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.
- 31 July 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (9) , 3753-3764
Rituximab in the COVID-19 era: The impact of albumin and IgG on patients with immune-mediated inflammatory diseases
Objective To identify factors associated with COVID-19 outcomes in patients with immune-mediated inflammatory diseases (IMID) treated with rituximab (RTX) and determine candidates for RTX administration/maintenance. Methods We conducted a case–control study of RTX-treated IMID patients with COVID-19 (May 2021–April 2023), including 32 hospitalized cases and 64 non-hospitalized controls matched by age, sex, IMID diagnosis. Logistic regression was used to analyze pre-COVID biochemical markers within 3-months and RTX-specific factors. Secondary outcomes in hospitalized cases included COVID-19 severity, viral shedding, and all-cause mortality. Results Higher RTX exposure was associated with reduced glucocorticoid dependence and higher pre-COVID albumin levels while correlated with lower IgG levels. However, lower pre-COVID albumin (OR: 0.231, p = 0.012) and higher maintenance glucocorticoid use (OR: 1.170, p = 0.007) were independently associated with hospitalization, regardless of IgG levels or RTX exposure. Among hospitalized cases, lower admission albumin (albumin_D0; OR: 0.029, p = 0.014) predicted severe COVID-19. Patients with albumin_D0 < 3.45 g/dL had higher mortality, regardless of IgG_D0 or RTX timing, and experienced prolonged viral shedding despite antiviral mono-therapy. Albumin_D0 ≥ 3.45 g/dL and IgG_D0 ≥ 687 mg/dL were associated with the lowest mortality risk. Timing of the last RTX dose did not influence secondary outcomes. Conclusion Pre-COVID albumin and glucocorticoid dependence are independently associated with hospitalization regardless of RTX-specific factors. Admission albumin predicts secondary outcomes. Risk of rituximab on COVID-19 outcomes is not universal. Albumin ≥ 3.45 g/dL and IgG ≥ 687 mg/dL identify lower-risk patients, providing guidance for safer RTX administration. Key Points • Risk of rituximab on COVID-19 outcomes in immune-mediated inflammatory diseases is not universal. Serum albumin and IgG levels are critical to determine the COVID-19 outcomes. • Patients with serum albumin ≥ 3.45 g/dL and IgG ≥ 687 mg/dL demonstrate a lower risk associated with rituximab, providing guidance for its safer administration in the post-COVID-19 era amidst potential challenges from emerging infections. • Serum albumin serves as a significant prognostic marker for COVID-19 outcomes in patients receiving rituximab treatment. • The timing of the most recent rituximab infusion does not affect COVID-19 outcomes in these patients.
- 31 July 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (9) , 3753-3764
Rituximab in the COVID-19 era: The impact of albumin and IgG on patients with immune-mediated inflammatory diseases
Objective To identify factors associated with COVID-19 outcomes in patients with immune-mediated inflammatory diseases (IMID) treated with rituximab (RTX) and determine candidates for RTX administration/maintenance. Methods We conducted a case–control study of RTX-treated IMID patients with COVID-19 (May 2021–April 2023), including 32 hospitalized cases and 64 non-hospitalized controls matched by age, sex, IMID diagnosis. Logistic regression was used to analyze pre-COVID biochemical markers within 3-months and RTX-specific factors. Secondary outcomes in hospitalized cases included COVID-19 severity, viral shedding, and all-cause mortality. Results Higher RTX exposure was associated with reduced glucocorticoid dependence and higher pre-COVID albumin levels while correlated with lower IgG levels. However, lower pre-COVID albumin (OR: 0.231, p = 0.012) and higher maintenance glucocorticoid use (OR: 1.170, p = 0.007) were independently associated with hospitalization, regardless of IgG levels or RTX exposure. Among hospitalized cases, lower admission albumin (albumin_D0; OR: 0.029, p = 0.014) predicted severe COVID-19. Patients with albumin_D0 < 3.45 g/dL had higher mortality, regardless of IgG_D0 or RTX timing, and experienced prolonged viral shedding despite antiviral mono-therapy. Albumin_D0 ≥ 3.45 g/dL and IgG_D0 ≥ 687 mg/dL were associated with the lowest mortality risk. Timing of the last RTX dose did not influence secondary outcomes. Conclusion Pre-COVID albumin and glucocorticoid dependence are independently associated with hospitalization regardless of RTX-specific factors. Admission albumin predicts secondary outcomes. Risk of rituximab on COVID-19 outcomes is not universal. Albumin ≥ 3.45 g/dL and IgG ≥ 687 mg/dL identify lower-risk patients, providing guidance for safer RTX administration. Key Points • Risk of rituximab on COVID-19 outcomes in immune-mediated inflammatory diseases is not universal. Serum albumin and IgG levels are critical to determine the COVID-19 outcomes. • Patients with serum albumin ≥ 3.45 g/dL and IgG ≥ 687 mg/dL demonstrate a lower risk associated with rituximab, providing guidance for its safer administration in the post-COVID-19 era amidst potential challenges from emerging infections. • Serum albumin serves as a significant prognostic marker for COVID-19 outcomes in patients receiving rituximab treatment. • The timing of the most recent rituximab infusion does not affect COVID-19 outcomes in these patients.
- Open Access
- 25 July 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (7) , 884
Response to comment on “Advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373”
- 25 July 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (7) , 884
Open AccessResponse to comment on “Advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373”
- Open Access
- 27 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (1) , 90-94
Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence
- 27 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (1) , 90-94
Open AccessPotential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence
- Open Access
- 1 January 1991
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 83 (1) , 10-16
Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease
We studied the cellular function and lymphokine production of T cells from patients with X‐linked lymphoproliferative disease (XLP) when activated by the challenge with Epstein‐Barr virus (EBV) infection. We used an assay system in which T cells were stimulated with membrane antigens of autologous EBV‐infected B lymphoblastoid cell lines (B‐LCL) and we examined cellular and humoral factors derived from the stimulated T cells which control the growth of EBV‐inlected B‐LCL. Immunoglobulin secretion from the autologous B‐LCL was suppressed with radiosensitive suppressor cells in the patients with XLP. The degree of suppression was correlated with the immunoglobulin levels in the serum of the patients with acquired hypogammaglobulinaemia (PP < 0.001). Moreover, the T cell supernatants from the patients with XLP were less potent to inhibit the B‐LCL growth. This diminished inhibition of the B‐LCL growth was correlated well with the decreased concentration of IFN‐γ in the T cell supernatants. These findings suggest that suppressor cells may be activated in the patients with the hypogammaglobulinaemia phenotype of XLP. but the frequent development of B cell lymphoma in hypogammaglobulinaemia indicate that immunoglobulin suppression may not exert enough pressure on the in vivo growth of EBV‐infected B cells. The defective secretion of IFN‐γ may be, at least partially, responsible for the abnormal cytotoxic T cell and natural killer activities found in the patients with XLP, and may indicate the clinical evaluation about the preventive injection of IFN‐γ against the development of malignant lymphoma.
- 1 January 1991
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 83 (1) , 10-16
Open AccessDefective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease
We studied the cellular function and lymphokine production of T cells from patients with X‐linked lymphoproliferative disease (XLP) when activated by the challenge with Epstein‐Barr virus (EBV) infection. We used an assay system in which T cells were stimulated with membrane antigens of autologous EBV‐infected B lymphoblastoid cell lines (B‐LCL) and we examined cellular and humoral factors derived from the stimulated T cells which control the growth of EBV‐inlected B‐LCL. Immunoglobulin secretion from the autologous B‐LCL was suppressed with radiosensitive suppressor cells in the patients with XLP. The degree of suppression was correlated with the immunoglobulin levels in the serum of the patients with acquired hypogammaglobulinaemia (PP < 0.001). Moreover, the T cell supernatants from the patients with XLP were less potent to inhibit the B‐LCL growth. This diminished inhibition of the B‐LCL growth was correlated well with the decreased concentration of IFN‐γ in the T cell supernatants. These findings suggest that suppressor cells may be activated in the patients with the hypogammaglobulinaemia phenotype of XLP. but the frequent development of B cell lymphoma in hypogammaglobulinaemia indicate that immunoglobulin suppression may not exert enough pressure on the in vivo growth of EBV‐infected B cells. The defective secretion of IFN‐γ may be, at least partially, responsible for the abnormal cytotoxic T cell and natural killer activities found in the patients with XLP, and may indicate the clinical evaluation about the preventive injection of IFN‐γ against the development of malignant lymphoma.